Ignite Creation Date:
2025-12-24 @ 2:55 PM
Ignite Modification Date:
2026-01-25 @ 4:35 PM
Study NCT ID:
NCT04666259
Status:
COMPLETED
Last Update Posted:
2025-10-16
First Post:
2020-12-07
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
Sponsor:
Novartis Pharmaceuticals
Organization:
Study Modules
Identification Module
Status Module
Sponsor Collaborators Module
Oversight Module
Description Module
Conditions Module
Design Module
Arms Interventions Module
Outcomes Module
Eligibility Module
Contacts Locations Module
References Module
Adverse Events Module
Baseline Characteristics Module
Participant Flow Module